PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
13.68%
Cash & equivalents growing 13.68% while AXSM's declined -10.45%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
13.68%
Below half of AXSM's -10.45%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.59%
Below half of AXSM's -10.32%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-11.93%
0.75-0.9x AXSM's -13.45%. Bill Ackman questions if competitor invests more heavily in future capacity.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-88.66%
Higher Other Non-Current Assets Growth compared to AXSM's zero value, indicating worse performance.
-8.29%
0.5-0.75x AXSM's -11.43%. Martin Whitman wonders if there's insufficient reinvestment vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
13.10%
Below half of AXSM's -10.33%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-14.12%
Less than half of AXSM's 8.28%. David Dodd sees a more disciplined AP approach or lower volume.
2.34%
Higher Short-Term Debt Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
14.12%
Higher Deferred Revenue (Current) Growth compared to AXSM's zero value, indicating better performance.
-2.34%
Higher Other Current Liabilities Growth compared to AXSM's zero value, indicating worse performance.
-12.65%
Above 1.5x AXSM's -7.49%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-36.66%
Less than half of AXSM's 0.05%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-14.12%
Above 1.5x AXSM's -2.39%. Michael Burry sees a potential leverage warning sign.
5.56%
Above 1.5x AXSM's 0.51%. Michael Burry suspects heavy new equity expansion or dilution.
-2.30%
Below half AXSM's -10.50%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.36%
Below half AXSM's 134.54%. Michael Burry sees potential underperformance in building shareholder capital.
13.10%
Below half AXSM's 180.84%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-14.09%
Less than half of AXSM's 0.00%. David Dodd sees less overall debt expansion vs. competitor.
-14.00%
Less than half of AXSM's 14.37%. David Dodd sees better deleveraging or stronger cash buildup than competitor.